OKUR

SEC source: 0001692747-26-000001 · form4-03242026_100303.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001609284-26-000001 · form4-03242026_100353.xml · nonDerivative · entry 1

Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,333

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001622769-26-000001 · form4-01022026_090120.xml · nonDerivative · entry 1

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,583

F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy.

SEC source: 0001193125-26-000942 · ownership.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,310

F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy.

SEC source: 0001692747-25-000004 · form4-12242025_011233.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,301

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

F4 · balance_after: Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025.

SEC source: 0001609284-25-000004 · form4-12242025_011243.xml · nonDerivative · entry 1

Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,419

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

F4 · balance_after: Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025.

SEC source: 0001622769-25-000003 · form4-10022025_081020.xml · nonDerivative · entry 1

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,325

F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy.

SEC source: 0001193125-25-228402 · ownership.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,399

F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy.

SEC source: 0001692747-25-000003 · form4-09242025_110914.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,603

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001609284-25-000003 · form4-09242025_110912.xml · nonDerivative · entry 1

Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,506

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-019052 · form4-07022025_080710.xml · nonDerivative · entry 1

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,780

F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy.

SEC source: 0000950170-25-093063 · ownership.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,274

F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy.

SEC source: 0001415889-25-018234 · form4-06252025_100636.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,906

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-018235 · form4-06252025_100613.xml · nonDerivative · entry 1

Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,594

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-015016 · form4-05302025_080515.xml · derivative · entry 1

Jansen Valerie Malyvanh · CIK 0001889716 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,650

Underlying: Class A Common Stock · 7,650 shares

Expires 2035-05-27

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

SEC source: 0001415889-25-015014 · form4-05302025_080501.xml · derivative · entry 1

Carruthers R Michael · CIK 0001644467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,650

Underlying: Class A Common Stock · 7,650 shares

Expires 2035-05-27

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

SEC source: 0001415889-25-015018 · form4-05302025_080518.xml · derivative · entry 1

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,650

Underlying: Class A Common Stock · 7,650 shares

Expires 2035-05-27

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

SEC source: 0001415889-25-015015 · form4-05302025_080510.xml · derivative · entry 1

GREY MICHAEL G · CIK 0001240122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,650

Underlying: Class A Common Stock · 7,650 shares

Expires 2035-05-27

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

SEC source: 0000950170-25-079841 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,650

Underlying: Class A Common Stock · 7,650 shares

Expires 2035-05-27

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

SEC source: 0001415889-25-015019 · form4-05302025_080528.xml · derivative · entry 1

Phillips Andrew John · CIK 0001921956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,650

Underlying: Class A Common Stock · 7,650 shares

Expires 2035-05-27

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

SEC source: 0000929638-25-001950 · form4.xml · nonDerivative · entry 1

Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner

Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · Former 10% Owner

Cormorant Private Healthcare Fund V LP · CIK 0001969296 · Former 10% Owner

Chen Bihua · CIK 0001599214 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F2 · price: Represents the weighted average sale price of Class A Common Stock (the "shares") sold in a series of open market transactions on the transaction date ranging from $1.85 to $2.03 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

F1 · ownership.nature: Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and Cormorant Private Healthcare Fund V, LP ("Fund V"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP.

SEC source: 0000950170-25-074459 · ownership.xml · nonDerivative · entry 2

ACORN BIOVENTURES, L.P. · CIK 0001766853 · 10% owner

ACORN CAPITAL ADVISORS GP, LLC · CIK 0001813692 · 10% owner

Hove Anders D · CIK 0001365618 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Acorn Bioventures 2, L.P.

Disclosed balance after: 1,129,730

F2 · ownership.direct: Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000950170-25-074459 · ownership.xml · nonDerivative · entry 1

ACORN BIOVENTURES, L.P. · CIK 0001766853 · 10% owner

ACORN CAPITAL ADVISORS GP, LLC · CIK 0001813692 · 10% owner

Hove Anders D · CIK 0001365618 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,709,944

F1 · ownership.direct: Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000929638-25-001870 · form4.xml · nonDerivative · entry 1

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · 10% owner

Cormorant Private Healthcare Fund V LP · CIK 0001969296 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,813,439

F1 · ownership.nature: Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and Cormorant Private Healthcare Fund V, LP ("Fund V"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP.

F2 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3 · ownership.nature: Represents (i) 429,934 shares of Class A Common Stock beneficially owned by the Master Fund, (ii) 1,099,451 shares of Class A Common Stock beneficially owned by Fund III, (iii) 234,125 shares of Class A Common Stock beneficially owned by Fund IV, and (iv) 49,929 shares of Class A Common Stock beneficially owned by Fund V.

SEC source: 0001415889-25-010418 · form4-04082025_090445.xml · nonDerivative · entry 2

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,209

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $2.57 to $3.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-010419 · form4-04082025_090410.xml · nonDerivative · entry 2

Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,682

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $2.57 to $3.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-010418 · form4-04082025_090445.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,053

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $3.10 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-010419 · form4-04082025_090410.xml · nonDerivative · entry 1

Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,198

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $3.10 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-009659 · form4-04022025_080441.xml · nonDerivative · entry 1

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,469

F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy.

SEC source: 0000950170-25-049473 · ownership.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,580

F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy.

SEC source: 0001415889-25-002310 · form4-01302025_010153.xml · derivative · entry 1

Hartley Dylan · CIK 0002037442 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Class A Common Stock · 45,000 shares

Expires 2035-01-26

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-25-002309 · form4-01302025_010108.xml · derivative · entry 1

Agresta Samuel · CIK 0001748961 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Class A Common Stock · 45,000 shares

Expires 2035-01-26

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-25-002311 · form4-01302025_010107.xml · derivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Class A Common Stock · 65,000 shares

Expires 2035-01-26

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-25-002312 · form4-01302025_010119.xml · derivative · entry 1

Saccomano Nicholas A · CIK 0001609284 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Class A Common Stock · 130,000 shares

Expires 2035-01-26

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001373604-24-000100 · form4.xml · nonDerivative · entry 2

Leonard Braden Michael · CIK 0001373603 · Former 10% owner of RPHM

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,076

F3 · price: Received in exchange for 1,020,769 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure").

SEC source: 0001373604-24-000100 · form4.xml · nonDerivative · entry 1

Leonard Braden Michael · CIK 0001373603 · Former 10% owner of RPHM

10b5-1 filing: No plan indicated

Ownership: Indirect · Holdings of BML Investment Partners, L.P.

Disclosed balance after: 345,739

F1 · price: Received in exchange for 3,457,395 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure").

F2 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-024914 · form4-10082024_111042.xml · derivative · entry 1

Hartley Dylan · CIK 0002037442 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,603

Underlying: Class A Common Stock · 137,603 shares

Expires 2034-10-03

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 9, 2025 and 1/48th of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024917 · form4-10082024_111035.xml · derivative · entry 1

Jansen Valerie Malyvanh · CIK 0001889716 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,300

Underlying: Class A Common Stock · 15,300 shares

Expires 2034-10-03

F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024911 · form4-10082024_111019.xml · derivative · entry 2

Agresta Samuel · CIK 0001748961 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,396

Underlying: Class A Common Stock · 131,396 shares

Expires 2034-10-03

F4 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024911 · form4-10082024_111019.xml · derivative · entry 1

Agresta Samuel · CIK 0001748961 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,588

Underlying: Class A Common Stock · 18,588 shares

Expires 2034-02-05

F2 · price: The Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR." Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, (footnote continued in footnote (3))

F3 · price: (continued from footnote (2)) a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024918 · form4-10082024_111036.xml · derivative · entry 4

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,611

Underlying: Class A Common Stock · 130,611 shares

Expires 2034-10-03

F6 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024918 · form4-10082024_111036.xml · derivative · entry 3

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,322

Underlying: Class A Common Stock · 5,322 shares

Expires 2033-08-29

F4 · price: Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F5 · derivative.exercise_date: 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024918 · form4-10082024_111036.xml · derivative · entry 2

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,781

Underlying: Class A Common Stock · 5,781 shares

Expires 2032-01-10

F4 · price: Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 3, 2023 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024918 · form4-10082024_111036.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,331

F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a "Service-Based Requirement" and a "Liquidity Event Plus Service Requirement." 1/16th of the RSUs met the "Service-Based" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2))

F2 · shares: (continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR."

F1 · price: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a "Service-Based Requirement" and a "Liquidity Event Plus Service Requirement." 1/16th of the RSUs met the "Service-Based" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2))

F2 · price: (continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR."

SEC source: 0001415889-24-024912 · form4-10082024_111033.xml · derivative · entry 5

Carruthers R Michael · CIK 0001644467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,300

Underlying: Class A Common Stock · 15,300 shares

Expires 2034-10-03

F6 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024912 · form4-10082024_111033.xml · derivative · entry 4

Carruthers R Michael · CIK 0001644467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,324

Underlying: Class A Common Stock · 1,324 shares

Expires 2033-08-29

F4 · price: Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F5 · derivative.exercise_date: 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024912 · form4-10082024_111033.xml · derivative · entry 3

Carruthers R Michael · CIK 0001644467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,760

Underlying: Class A Common Stock · 1,760 shares

Expires 2031-07-06

F4 · price: Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001415889-24-024912 · form4-10082024_111033.xml · nonDerivative · entry 2

Carruthers R Michael · CIK 0001644467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,939

F2 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a "Service-Based Requirement" and a "Liquidity Event Plus Service Requirement." 1/16th of the RSUs met the "Service-Based" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. At the effective time of the Merger, each RSU of OnKure was assumed by, and converted into an RSU award of, Reneo covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share).

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), on October 4, 2024, Merger Sub I merged with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). At the effective time of the Merger, each share of OnKure common stock and Series C preferred stock was converted into the right to receive a number of shares of Reneo Class A Common Stock determined by multiplying each such share by a designated exchange exchange ratio (rounded down to the nearest whole share). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR."

SEC source: 0001415889-24-024912 · form4-10082024_111033.xml · nonDerivative · entry 1

Carruthers R Michael · CIK 0001644467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 874

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), on October 4, 2024, Merger Sub I merged with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). At the effective time of the Merger, each share of OnKure common stock and Series C preferred stock was converted into the right to receive a number of shares of Reneo Class A Common Stock determined by multiplying each such share by a designated exchange exchange ratio (rounded down to the nearest whole share). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR."

SEC source: 0001415889-24-024919 · form4-10082024_111032.xml · derivative · entry 1

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,300

Underlying: Class A Common Stock · 15,300 shares

Expires 2034-10-03

F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.